Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Sierra J, Montesinos P, Thomas X, Griskevicius L, Cluzeau T, Caillot D, Legrand O, Minotti C, Luppi M, Farkas F, Bengoudifa BR, Gilotti G, Hodzic S, Rambaldi A, Venditti A. Sierra J, et al. Among authors: cluzeau t. Blood Adv. 2023 Nov 14;7(21):6441-6450. doi: 10.1182/bloodadvances.2023009847. Blood Adv. 2023. PMID: 37581981 Free PMC article. Clinical Trial.
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T. Devillier R, et al. Among authors: cluzeau t. Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. Br J Haematol. 2016. PMID: 26061174 Free article. No abstract available.
Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.
Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, Devys A, De Matteis M, Dubois V, Filloux M, Fort M, Hau F, Jollet I, Labalette M, Masson D, Mercier B, Pedron B, Perrier P, Picard C, Quainon F, Ramounau-Pigot A, Renac V, Van Endert P, Charron D, Peffault de la Tour R, Taupin JL, Loiseau P. Cluzeau T, et al. Bone Marrow Transplant. 2016 May;51(5):687-91. doi: 10.1038/bmt.2015.351. Epub 2016 Feb 8. Bone Marrow Transplant. 2016. PMID: 26855158
[Management of myelodysplastic syndromes].
Duchmann M, Fenaux P, Cluzeau T. Duchmann M, et al. Among authors: cluzeau t. Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26. Bull Cancer. 2015. PMID: 26410692 Review. French.
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.
Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G. Dubois A, et al. Among authors: cluzeau t. Oncotarget. 2016 May 3;7(18):26120-36. doi: 10.18632/oncotarget.8319. Oncotarget. 2016. PMID: 27027430 Free PMC article.
123 results